We are live on ! Find out more

817 hedge funds and large institutions have $11.9B invested in GSK in 2020 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 267 increasing their positions, 338 reducing their positions, and 133 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more call options, than puts

Call options by funds: $113M | Put options by funds: $64.4M

0.37% more ownership

Funds ownership: 4.62%5% (+0.37%)

0% more funds holding in top 10

Funds holding in top 10: 1616 (0)

9% less funds holding

Funds holding: 894817 (-77)

12% less capital invested

Capital invested by funds: $13.5B → $11.9B (-$1.67B)

21% less repeat investments, than reductions

Existing positions increased: 267 | Existing positions reduced: 338

48% less first-time investments, than exits

New positions opened: 69 | Existing positions closed: 133

Holders
817
Holders Change
-77
Holders Change %
-8.61%
% of All Funds
18%
Holding in Top 10
16
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.35%
New
69
Increased
267
Reduced
338
Closed
133
Calls
$113M
Puts
$64.4M
Net Calls
+$48.4M
Net Calls Change
+$13.1M
Name Holding Trade Value Shares
Change
Change in
Stake
D.E. Shaw & Co
51
D.E. Shaw & Co
New York
$31.9M +$35.9M +673,218 New
Charles Schwab
52
Charles Schwab
California
$31.8M +$1.58M +29,680 +5%
LBA
53
Letko, Brosseau & Associates
Quebec, Canada
$29.4M -$108K -2,020 -0.3%
Stifel Financial
54
Stifel Financial
Missouri
$26M -$8.65M -162,154 -23%
HighTower Advisors
55
HighTower Advisors
Illinois
$25.6M +$3.58M +67,031 +14%
LPL Financial
56
LPL Financial
California
$24.9M -$1.33M -24,890 -5%
WF
57
Welch & Forbes
Massachusetts
$24.7M
Natixis Advisors
58
Natixis Advisors
Massachusetts
$24.3M +$533K +9,995 +2%
Invesco
59
Invesco
Georgia
$24M -$368K -6,907 -1%
AIA
60
Avalon Investment & Advisory
Texas
$23.9M +$2.08M +39,008 +8%
Connor, Clark & Lunn Investment Management (CC&L)
61
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$23.4M +$26.3M +493,720 New
BCAM
62
Boston Common Asset Management
Massachusetts
$22.1M +$24.9M +466,518 New
LSV Asset Management
63
LSV Asset Management
Illinois
$21.4M +$380K +7,120 +2%
CAPTRUST Financial Advisors
64
CAPTRUST Financial Advisors
North Carolina
$21.2M +$660K +12,371 +3%
Primecap Management
65
Primecap Management
California
$21.2M
SAM
66
Silvercrest Asset Management
New York
$20.3M -$115K -2,160 -0.5%
EP
67
Eversept Partners
New York
$19.9M -$21.9M -410,011 -50%
CIBC World Market
68
CIBC World Market
Ontario, Canada
$19.2M +$1.91M +35,767 +10%
CIC
69
Crawford Investment Counsel
Georgia
$18.3M -$12.9M -241,804 -38%
SEI Investments
70
SEI Investments
Pennsylvania
$18.3M -$762K -14,294 -4%
Grantham, Mayo, Van Otterloo & Co (GMO)
71
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$17.4M +$11.3M +211,120 +134%
Two Sigma Advisers
72
Two Sigma Advisers
New York
$17.4M +$18M +336,613 +1,071%
JP Morgan Chase
73
JP Morgan Chase
New York
$17.2M -$41.9M -785,969 -68%
Commonwealth Equity Services
74
Commonwealth Equity Services
Massachusetts
$16.8M +$479K +8,972 +3%
SC
75
Saturna Capital
Washington
$16.5M +$576K +10,804 +3%

GSK Hedge Fund Activity: Q1 2020 in Review

817 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2020, worth a combined $11.9B — down 12% from $13.5B a quarter earlier.

Sellers outnumbered buyers: 133 funds closed out of GSK and 69 opened new positions — a net loss of 64 holders — while 338 trimmed existing stakes and 267 added.

The largest buyer was Capital International Investors, adding an estimated $378M. The largest seller was Dodge & Cox, cutting an estimated $100M.

  • 817 institutional investors held GSK (GSK) as of Q1 2020, down from 894 in Q4 2019.
  • Funds reported $11.9B of GSK stock for Q1 2020, down 12% quarter-over-quarter.
  • 69 funds opened new GSK positions in Q1 2020 and 133 closed out, a net change of -64 holders.
  • The largest GSK buyer in Q1 2020 was Capital International Investors, an estimated $378M added.
  • The largest GSK seller in Q1 2020 was Dodge & Cox, an estimated $100M sold.

Based on aggregated 13F filings for Q1 2020.